Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium
compared to placebo over 12 week treatment period. Tiotropium inhalation solution will be
delivered via Respimat inhaler and will be examined on top of maintenance inhaled
corticosteroid treatment in patients with mild persistent asthma. Efficacy and safety will be
assessed by measuring the effects on lung functions, effects on lung exacerbations, effects
on asthma control and numbers of adverse events.